Stay updated on MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial
Sign up to get notified when there's something new on the MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial page.

Latest updates to the MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial page
- Check7 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference0.8%
- Check14 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.0%
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.0%
- Check36 days agoChange DetectedThe website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant change in this functionality.SummaryDifference0.1%
- Check65 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.0%
- Check72 days agoChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information for inquiries about joining the study and includes a reference to the Contacts and Locations section in the How to Read a Study Record.SummaryDifference2%
Stay in the know with updates to MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial page.